These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 34858228)
1. Efficacy and Safety of Zhou J; Chen X; Xiao L; Zhou J; Feng L; Wang G Front Psychiatry; 2021; 12():754921. PubMed ID: 34858228 [No Abstract] [Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression. Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348 [TBL] [Abstract][Full Text] [Related]
5. Novel Augmentation Strategies in Major Depression. Martiny K Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173 [TBL] [Abstract][Full Text] [Related]
6. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial. Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564 [TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624 [TBL] [Abstract][Full Text] [Related]
9. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204 [TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Goldstein DJ; Lu Y; Detke MJ; Wiltse C; Mallinckrodt C; Demitrack MA J Clin Psychopharmacol; 2004 Aug; 24(4):389-99. PubMed ID: 15232330 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049 [TBL] [Abstract][Full Text] [Related]
12. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467 [TBL] [Abstract][Full Text] [Related]
13. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423 [TBL] [Abstract][Full Text] [Related]
14. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
15. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641 [TBL] [Abstract][Full Text] [Related]
16. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888 [TBL] [Abstract][Full Text] [Related]
17. Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression. Mallinckrodt CH; Goldstein DJ; Detke MJ; Lu Y; Watkin JG; Tran PV Prim Care Companion J Clin Psychiatry; 2003 Feb; 5(1):19-28. PubMed ID: 15156243 [TBL] [Abstract][Full Text] [Related]
18. A 12-week, randomized, double-blind, placebo-controlled study evaluating the effect of eszopiclone 2 mg on sleep/wake function in older adults with primary and comorbid insomnia. Ancoli-Israel S; Krystal AD; McCall WV; Schaefer K; Wilson A; Claus R; Rubens R; Roth T Sleep; 2010 Feb; 33(2):225-34. PubMed ID: 20175406 [TBL] [Abstract][Full Text] [Related]
19. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms. Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411 [TBL] [Abstract][Full Text] [Related]
20. Clinical Efficacy of the Chinese Herbal Medicine Shumian Capsule for Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial. Chen S; Xu Z; Li Y; Wang T; Yue Y; Hou Z; You L; Lu N; Yin Y; Liu X; Tan L; Ji H; Shi Y; Xin X; Jiang W; Yuan Y Neuropsychiatr Dis Treat; 2022; 18():669-679. PubMed ID: 35378821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]